A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
Stopped This study was challenged by the incidence of KHE with KMP as this continued to be extremely rare, and very sporadic. In July of 2019 grant renewal funding ended.
Conditions
- Kaposiform Hemangioendothelioma (KHE)
- Kasabach-Merritt Syndrome
- Tufted Angioma
Interventions
- DRUG: Vincristine
- DRUG: Sirolimus
Sponsor
Boston Children's Hospital
Collaborators